{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:37:14Z","timestamp":1784266634225,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["SCCV2537"],"award-info":[{"award-number":["SCCV2537"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vph.2017.12.065","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T13:38:38Z","timestamp":1513863518000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis"],"prefix":"10.1016","volume":"107","author":[{"given":"Jochen","family":"Dutzmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Sedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2017.12.065_bb0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2017.12.065_bb0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.coph.2012.12.007","article-title":"Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications","volume":"13","author":"Zwadlo","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.vph.2017.12.065_bb0015","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/nm1102-1249","article-title":"Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies","volume":"8","author":"Dzau","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2017.12.065_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fendo.2015.00153","article-title":"Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis","volume":"6","author":"Moss","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.vph.2017.12.065_bb0025","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/ATVBAHA.115.307031","article-title":"Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1\/NF-kappaB pathways","volume":"36","author":"Sun","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.12.065_bb0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2017.01.013","article-title":"Essential role of ICAM-1 in aldosterone-induced atherosclerosis","volume":"232","author":"Marzolla","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors","volume":"34","author":"Pruthi","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.12.065_bb0040","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1172\/JCI40205","article-title":"Placental growth factor mediates aldosterone-dependent vascular injury in mice","volume":"120","author":"Jaffe","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2017.12.065_bb0045","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2017.12.065_bb0050","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2017.12.065_bb0055","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2017.12.065_bb0060","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2017.12.065_bb0065","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2017.12.065_bb0070","first-page":"706","article-title":"Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque","volume":"28","author":"de Rita","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.vph.2017.12.065_bb0075","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(58)92464-4","article-title":"The use of a steroidal spirolactone in the treatment of ascites in hepatic cirrhosis","volume":"2","author":"Kerr","year":"1958","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2017.12.065_bb0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJM196108242650802","article-title":"A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents","volume":"265","author":"Ogden","year":"1961","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2017.12.065_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bjp.0706098","article-title":"Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms","volume":"144","author":"Cassis","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2017.12.065_bb0090","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2017.12.065_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tcm.2008.11.004","article-title":"Monocyte-endothelial cell interactions in the development of atherosclerosis","volume":"18","author":"Mestas","year":"2008","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.vph.2017.12.065_bb0100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2017.12.065_bb0105","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/01.ATV.0000258414.59393.89","article-title":"Mineralocorticoid receptor activation promotes vascular cell calcification","volume":"27","author":"Jaffe","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.12.065_bb0110","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/ATVBAHA.111.229070","article-title":"Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways","volume":"31","author":"Newfell","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.12.065_bb0115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1677\/joe.0.1650533","article-title":"Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation","volume":"165","author":"Xiao","year":"2000","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.vph.2017.12.065_bb0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.05674","article-title":"Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice","volume":"66","author":"DeMarco","year":"2015","journal-title":"Hypertension"},{"issue":"269","key":"10.1016\/j.vph.2017.12.065_bb0125","article-title":"Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO\/GC signaling","volume":"6","author":"Silva","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0130","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","article-title":"Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression","volume":"39","author":"Bauersachs","year":"2002","journal-title":"J. Am.Coll. Cardiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0135","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijcard.2006.05.069","article-title":"Effect of spironolactone on C-reactive protein levels in patients with heart disease","volume":"117","author":"Godfrey","year":"2007","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1161\/HYPERTENSIONAHA.110.163444","article-title":"C-reactive protein makes human endothelium stiff and tight","volume":"57","author":"Kusche-Vihrog","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2017.12.065_bb0145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2017.12.065_bb0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2337\/db14-0670","article-title":"Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes","volume":"64","author":"Garg","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.vph.2017.12.065_bb0155","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(96)88542-7","article-title":"Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist","volume":"29","author":"Van Belle","year":"1995","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2017.12.065_bb0165","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12020-012-9675-2","article-title":"Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK","volume":"42","author":"GX","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.vph.2017.12.065_bb0170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/hc3001.091458","article-title":"Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries","volume":"104","author":"Ward","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.12.065_bb0175","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MJT.0b013e31818bec62","article-title":"Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites","volume":"16","author":"Bacchetta","year":"2009","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.vph.2017.12.065_bb0180","doi-asserted-by":"crossref","first-page":"769","DOI":"10.47102\/annals-acadmedsg.Hurkan","article-title":"Spironolactone does not prevent restenosis after coronary stenting in humans","volume":"33","author":"Kursaklioglu","year":"2004","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.vph.2017.12.065_bb0185","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/FJC.0b013e31826f5535","article-title":"Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice","volume":"60","author":"Raz-Pasteur","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2017.12.065_bb0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1470320312467558","article-title":"Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice","volume":"15","author":"Raz-Pasteur","year":"2014","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"10.1016\/j.vph.2017.12.065_bb0195","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/en.2010-0925","article-title":"11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe\u2212\/\u2212 mice","volume":"152","author":"Deuchar","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.vph.2017.12.065_bb0200","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2016.06.018","article-title":"Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism","volume":"251","author":"Kratz","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2017.12.065_bb0205","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.HYP.0000184640.81730.22","article-title":"Eplerenone inhibits atherosclerosis in nonhuman primates","volume":"46","author":"Takai","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2017.12.065_bb0210","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.12.065_bb0215","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1093\/eurheartj\/eht095","article-title":"Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity","volume":"34","author":"Schafer","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2017.12.065_bb0220","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","article-title":"Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation","volume":"26","author":"Suzuki","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.12.065_bb0225","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0008-6363(03)00333-X","article-title":"Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction","volume":"58","author":"Schafer","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2017.12.065_bb0230","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.107.093450","article-title":"Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction","volume":"50","author":"Sartorio","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2017.12.065_bb0235","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0029-1243253","article-title":"Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists","volume":"42","author":"Schupp","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.vph.2017.12.065_bb0240","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/HJH.0b013e32832bd284","article-title":"Eplerenone does not attenuate diabetes-associated atherosclerosis","volume":"27","author":"Koh","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2017.12.065_bb0245","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","article-title":"Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice","volume":"41","author":"Keidar","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2017.12.065_bb0250","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","article-title":"Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone","volume":"109","author":"Keidar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.12.065_bb0255","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/HYPERTENSIONAHA.107.104299","article-title":"Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability","volume":"51","author":"Imanishi","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2017.12.065_bb0260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.vph.2016.04.005","article-title":"Novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification","volume":"86","author":"Zhu","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2017.12.065_bb0265","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1210\/en.2010-0350","article-title":"Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells","volume":"151","author":"Cascella","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.vph.2017.12.065_bb0270","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/clc.22528","article-title":"Vascular effects of Eplerenone in coronary artery disease with preserved ejection fraction: a double-blind, randomized, placebo-controlled trial","volume":"39","author":"Sudano","year":"2016","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0275","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2014.01.017","article-title":"Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation","volume":"167","author":"Bavry","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.vph.2017.12.065_bb0280","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/HJH.0000000000001264","article-title":"Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension","volume":"35","author":"Schneider","year":"2017","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2017.12.065_bb0285","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2017.12.065_bb0290","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijcard.2005.03.078","article-title":"Eplerenone suppresses neointimal formation after coronary stent implantation in swine","volume":"107","author":"Wakabayashi","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0295","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","article-title":"Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction","volume":"42","author":"Fraccarollo","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2017.12.065_bb0300","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1210\/en.2012-1481","article-title":"Contribution of endogenous glucocorticoids and their intravascular metabolism by 11beta-HSDs to postangioplasty neointimal proliferation in mice","volume":"153","author":"Iqbal","year":"2012","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.vph.2017.12.065_bb0305","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1096\/fj.201700317R","article-title":"The glucocorticoid receptor in monocyte-derived macrophages is critical for cardiac infarct repair and remodeling","volume":"31","author":"Galuppo","year":"2017","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.vph.2017.12.065_bb0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2017.12.065_bb0315","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","article-title":"Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction","volume":"67","author":"Gueret","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2017.12.065_bb0320","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1681\/ASN.2016040477","article-title":"Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1","volume":"28","author":"Barrera-Chimal","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.vph.2017.12.065_bb0325","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2017.12.065_bb0330","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of Finerenone vs. Eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ. J."},{"issue":"9","key":"10.1016\/j.vph.2017.12.065_bb0335","doi-asserted-by":"crossref","first-page":"e0184888","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS One"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117302811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117302811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:17:32Z","timestamp":1761527852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189117302811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":67,"alternative-id":["S1537189117302811"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2017.12.065","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2017.12.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}